Shanghai Medicilon Inc (688202) - Total Assets
Based on the latest financial reports, Shanghai Medicilon Inc (688202) holds total assets worth CN¥2.88 Billion CNY (≈ $421.57 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shanghai Medicilon Inc - Total Assets Trend (2016–2025)
This chart illustrates how Shanghai Medicilon Inc's total assets have evolved over time, based on quarterly financial data. Also see 688202 market cap overview for the company's overall valuation and market capitalisation.
Shanghai Medicilon Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Shanghai Medicilon Inc's total assets of CN¥2.88 Billion consist of 46.5% current assets and 53.6% non-current assets. Review debt load of Shanghai Medicilon Inc to assess the company's total debt and financial obligations.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 10.9% |
| Accounts Receivable | CN¥408.31 Million | 15.6% |
| Inventory | CN¥112.22 Million | 4.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥269.20 Million | 10.3% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Shanghai Medicilon Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Shanghai Medicilon Inc stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Medicilon Inc's current assets represent 46.5% of total assets in 2025, a decrease from 69.9% in 2016.
- Cash Position: Cash and equivalents constituted 10.9% of total assets in 2025, down from 41.8% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 15.6% of total assets.
Shanghai Medicilon Inc Competitors by Total Assets
Key competitors of Shanghai Medicilon Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Celldex Therapeutics Inc
NASDAQ:CLDX
|
USA | $511.25 Million |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
USA | $452.70 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Savara Inc
NASDAQ:SVRA
|
USA | $192.14 Million |
Shanghai Medicilon Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.84 | 2.70 | 2.42 |
| Quick Ratio | 1.57 | 2.56 | 2.24 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥653.23 Million | CN¥912.64 Million | CN¥401.53 Million |
Shanghai Medicilon Inc - Advanced Valuation Insights
This section examines the relationship between Shanghai Medicilon Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.99 |
| Latest Market Cap to Assets Ratio | 0.80 |
| Asset Growth Rate (YoY) | -7.1% |
| Total Assets | CN¥2.62 Billion |
| Market Capitalization | $2.09 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Medicilon Inc's assets below their book value (0.80x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shanghai Medicilon Inc's assets decreased by 7.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shanghai Medicilon Inc (2016–2025)
The table below shows the annual total assets of Shanghai Medicilon Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.62 Billion ≈ $383.69 Million |
-7.13% |
| 2024-12-31 | CN¥2.82 Billion ≈ $413.13 Million |
-13.55% |
| 2023-12-31 | CN¥3.27 Billion ≈ $477.90 Million |
+40.19% |
| 2022-12-31 | CN¥2.33 Billion ≈ $340.89 Million |
+29.89% |
| 2021-12-31 | CN¥1.79 Billion ≈ $262.46 Million |
+31.46% |
| 2020-12-31 | CN¥1.36 Billion ≈ $199.64 Million |
+20.92% |
| 2019-12-31 | CN¥1.13 Billion ≈ $165.11 Million |
+138.57% |
| 2018-12-31 | CN¥472.95 Million ≈ $69.21 Million |
+21.39% |
| 2017-12-31 | CN¥389.61 Million ≈ $57.01 Million |
+12.96% |
| 2016-12-31 | CN¥344.90 Million ≈ $50.47 Million |
-- |
About Shanghai Medicilon Inc
Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers drug discovery, CMC development, preclinical research, biology, chemistry, catalyst screening, flow ch… Read more